Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Velocity-Loss Training and Parkinson's Disease

25. september 2026 opdateret af: Joseph Signorile, University of Miami

Comparison of Neuromuscular and Functional Adaptations to 10% and 30% Velocity-Loss Threshold Resistance Training in Persons With Parkinson's Disease

This study will compare the effects of velocity-loss resistance training at 10% and 30% velocity loss thresholds on measures of muscle strength and power and tests of daily performance in older adults with Parkinson's disease.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Florida
      • Coral Gables, Florida, Forenede Stater, 33147
        • Rekruttering
        • Laboratory of Neruomuscular Research and Active Aging
        • Kontakt:
        • Ledende efterforsker:
          • Joseph Signorile, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Parkinson's Disease Hoehn & Yahr Stages 1-3
  • Able to walk 50 meters unassisted
  • Able to understand and communicate in English

Exclusion Criteria:

  • Uncontrolled cardiovascular or other neuromuscular disease that prevent participation in a training program
  • Any systemic inflammatory or autoimmune conditions such as rheumatoid arthritis, or other serious concomitant medical illness
  • Unresolved injury or surgery to the upper or lower limbs that prevents weight training.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: 10% Velocity-Loss Threshold Resistance Training

Participants will receive velocity-based resistance training at 10% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.

Participants will receive a total of twenty-four 45-minutes in-person training sessions at 10% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.

Eksperimentel: 30% Velocity-Loss Threshold Resistance Training

Participants will receive velocity-based resistance training at 30% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.

Participants will receive a total of twenty-four 45-minutes in-person training sessions at 30% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in neuromuscular performance as measured by 1-repetition maximum (1RM)
Tidsramme: Baseline, 12 weeks

Maximal load that can be lifted in one repetition (1RM) will be assessed in both leg press and chest press exercises. The loads on the testing equipment will be increased across 5 to 7 testing repetitions. The persons 1RM will be the highest load the person can move through the range of motion of the exercise. There are no minimum or maximum scores for this test. The higher the 1RM the stronger the person is. The unit of measurement is kilograms.

Baseline, 12 weeks
Change in neuromuscular performance as measured by Watts
Tidsramme: Baseline, 12 weeks

This test measures the power a person can produce at maximal speed using loads of 20%, 40%, 60%, 80%, and 90% of 1RM for the chest press and leg press. Power shows how fast a person can do work. There are no minimum or maximum possible values. Higher values indicate better neuromuscular performance. Unit of measure is Watts.

Baseline, 12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in the Speed of the Ten-Meter Walk Test.
Tidsramme: Baseline, 12 weeks

The ten-meter walk test will be used to assess gait velocity. The participants will be asked to walk at usual walking speed and as quickly as possible in a straight line on a 10-meter (m) course marked at 0, 2, 8 and 10 m. On verbal command, participants will start on the 0-m mark and stop when the 10-m mark is crossed. The total time to ambulate from the 2-m mark to the 8-m mark (6 m total) will be timed to the hundredth of a second. Two trials will be performed at each speed, and the average will be documented in meters per second. One-minute recoveries will be provided between trials.

Baseline, 12 weeks
Change in Time for the Five Times Sit-to-Stand Test.
Tidsramme: Baseline, 12 weeks

The five-time sit-to-stand test will be used to assess functional lower body strength. The participant will sit with arms folded across the chest and the back against the chair. On a verbal command, the participant will stand up and sit down five times as quickly as possible. Timing begins at the word go and ends when the buttocks touch the chair after the fifth repetition. One practice and two testing trials will be performed. Time will be measured in seconds.

Baseline, 12 weeks
Change in the time required to complete the timed Up-and-Go Test.
Tidsramme: Baseline, 12 weeks

Upon verbal cue, participants will stand up, walk around a cone placed three meters from the front edge of the chair and then returns to a seated position as quickly as possible. Time is measured in seconds.

Baseline, 12 weeks
Change in Distance of the Seated Medicine Ball Throw.
Tidsramme: Baseline, 12 weeks

Upper body power will be assessed using the Seated Medicine Ball Throw test. Participants will sit in an armless chair with their back against the chair back and throw a 6-pound medicine ball from the chest as far as possible at an approximate 45-degree angle. Participants will complete three recorded test attempts. The distance thrown in meters will be measured. There are no minimum or maximum possible values. Greater throwing distances indicate better upper body power.

Baseline, 12 weeks
Change in Muscle Thickness using Ultrasound.
Tidsramme: Baseline, 12 weeks

Muscle thickness will be assessed using B-mode ultrasonography. Three longitudinal-view images will be obtained for each muscle assessed. Muscle thickness will be measured by drawing a perpendicular line from the superficial aponeurosis to the deep aponeurosis at the thickest region of the muscle. Assessments will be performed on selected thigh and upper arm muscles. Muscle thickness is measured in centimeters (cm). Higher values indicate greater muscle thickness.

Baseline, 12 weeks
Change in Muscle Quality using Ultrasound.
Tidsramme: Baseline, 12 weeks

Muscle quality will be measured using a gray scale. Grayscale values range from 0 to 255 units, where lower values (darker pixels) indicate greater muscle tissue content and higher values (lighter pixels) indicate greater intramuscular fat. The muscle to be tested will be the thigh muscles and the back of your arm. Lower grayscale values indicate better muscle quality.

Baseline, 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Joseph F. Signorile, PhD, University of Miami - Coral Gables Campus

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. september 2026

Primær færdiggørelse (Anslået)

30. december 2026

Studieafslutning (Anslået)

30. december 2026

Datoer for studieregistrering

Først indsendt

18. september 2026

Først indsendt, der opfyldte QC-kriterier

18. september 2026

Først opslået (Faktiske)

25. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 20260975

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .